Iovance Biotherapeutics
IOVA · What the business does, what can go wrong, and how options sellers approach it
What it does
Iovance Biotherapeutics is a biotechnology company that develops cancer treatments made from a patient's own immune cells. Its approach uses tumor-infiltrating lymphocytes (TIL): immune cells grown in a lab from a piece of the patient's tumor, then infused back to attack the cancer.
Its approved TIL cell therapy treats advanced melanoma. The company is also testing the approach in other solid tumors.
How it makes money
Revenue comes from product sales, led by its TIL cell therapy for melanoma plus an IL-2 product used alongside it. Each dose is made for one patient, so the process is complex and costly. Manufacturing capacity, logistics and hospital readiness all affect how fast sales can grow.
The company has historically spent more than it earns, funding research and manufacturing through share sales and other financing.
Why investors own it
- Exposure to a new type of cancer treatment that could reach more tumor types if trials succeed.
- A product already on the market, which separates it from many earlier-stage biotechs.
What can go wrong
- Clinical trials can fail or show weaker results than hoped.
- Regulators can delay or reject new uses.
- Treatment is complicated, requires specialized hospitals and carries serious side effects, which can slow adoption.
- Manufacturing is hard to scale and expensive.
- Continued losses may force share sales that dilute existing holders.
- Competing cancer treatments, including other cell therapies and immunotherapies, could limit its market.
What to watch
- Product sales and the number of treatment centers active
- Clinical trial data in new tumor types
- Regulatory filings and decisions
- Cash balance, cash burn and new share offerings
- Manufacturing capacity and production reliability
- Insurance coverage and reimbursement trends
Options income angle
Options on IOVA trade across many expirations, with decent liquidity near the current price, though spreads can widen for distant strikes and longer dates.
Implied volatility tends to be elevated. It is driven mainly by trial results, regulatory decisions, quarterly sales updates and financing news, and it often rises ahead of those events and drops afterward.
One caution for sellers of premium: biotech shares can gap sharply on a single announcement. A covered call caps gains on a jump, and a short put can be assigned well above where the stock later trades. High premiums reflect real risk.
Follow IOVA in Kortex
The Kortex app shows IOVA's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.